跳至主導覽 跳至搜尋 跳過主要內容

Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus

  • Pei Hung Chang
  • , Meng Che Hsieh
  • , Hao Wei Teng
  • , Yi Hsin Liang
  • , Hong Hwa Chen
  • , Hung Chih Hsu
  • , Jeng Kai Jiang
  • , Feng Fan Chiang
  • , Johnson Lin
  • , Been Ren Lin
  • , Yao Yu Hsieh
  • , Tao Wei Ke
  • , Feng Che Kuan
  • , Wen Shih Huang
  • , Bo Wen Lin
  • , Yu Yao Chang
  • , Yu Li Su
  • , William Tzu Liang Chen
  • , Chien Kuo Liu*
  • , Jaw Yuan Wang*
  • *此作品的通信作者
  • E-Da Cancer Hospital
  • I-Shou University
  • Veterans General Hospital-Taipei
  • National Yang Ming Chiao Tung University
  • National Taiwan University
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • National Tsing Hua University
  • Veterans General Hospital-Taichung Taiwan
  • Providence University Taiwan
  • Mackay Memorial Hospital Taiwan
  • Taipei Medical University
  • China Medical University Taichung
  • National Cheng Kung University
  • Changhua Christian Hospital
  • National Chung Hsing University
  • Chang Jung Christian University
  • National Sun Yat-sen University
  • China Medical University Hsinchu Hospital
  • Kaohsiung Medical University

研究成果: 期刊稿件 › 文章 › 同儕審查

摘要

Background: Metastatic colorectal cancer (mCRC) is a major public health burden in Taiwan. Despite multiple later-line therapies, outcomes remain suboptimal. International guidelines provide valuable direction, but are difficult to apply locally due to differences in drug accessibility, reimbursement policies, and practice patterns. Objectives: This initiative developed a Taiwan-specific, consensus framework for managing mCRC in the third line and beyond. Design: This consensus integrated global evidence with local practice, real-world data, and reimbursement considerations. Methods: A multidisciplinary panel of 20 experts convened by the Taiwan Society of Colon and Rectal Surgeons (TSCRS) used a modified Delphi process. Initial recommendations were adapted from European Society for Medical Oncology (ESMO), Pan-Asian ESMO, and National Comprehensive Cancer Network (NCCN) guidelines, supplemented by Taiwan real-world data. Consensus was achieved through three structured rounds of voting and discussion, with final statements graded by level of evidence and strength of agreement. Results: Twelve recommendations spanning three domains were endorsed: disease management, third-line options, and extended strategies. Key local adaptations include aligning imaging schedule intervals with Taiwan’s National Health Insurance reimbursement policies and prioritizing trifluridine/tipiracil and regorafenib as preferred third-line agents. The panel acknowledged emerging options such as fruquintinib, epidermal growth factor receptor antibody rechallenge, and novel chemotherapy combinations. While the panel strongly supported biomarker-informed treatments, their broader implementation is constrained by limited reimbursement coverage for next-generation sequencing. Other challenges included limited drug access, suboptimal uptake of biomarker testing, and reimbursement constraints. Conclusion: This Taiwan-specific consensus provides a practical, evidence-based framework for late-line mCRC treatment, bridging global standards with local realities to improve policy alignment and optimize patient outcomes.

原文英語
頁(從 - 到)17588359261457553
期刊Therapeutic Advances in Medical Oncology
卷18
DOIs
出版品狀態已出版 - 01 01 2026

文獻附註

© The Author(s), 2026.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG1 消除貧窮
    SDG1 消除貧窮
  2. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus」主題。共同形成了獨特的指紋。

引用此